Biosceptre’s Phase 1 Clinical Trial for anti-cancer vaccine BIL06v approved by Ethics Committee
On the 21st of February Biosceptre's proposed Phase I clinical [...]
Biosceptre welcomes Tuspark S & T into its Series A fund raising round
Biosceptre has received over £8M into its’ series A raise [...]
Biosceptre Joins European Cooperation in Science & Technology COST Group BMBS 1406 – with focus on Ion Channels and Immune Response
Biosceptre announces today its membership of the COST Group [...]
Professor Paul de Souza joins Biosceptre executive team as Chief Medical Officer
Biosceptre's appointment of a CMO marks a major milestone [...]
Biosceptre’s Phase 1 Clinical Trial for anti-cancer antibody BIL03s approved by Ethics Committee
Biosceptre’s proposed Phase I clinical trial for BIL03s (anti-cancer monoclonal [...]
Biosceptre publishes a clinical study of topical drug BIL010t as therapy for BCC
Biosceptre has published a clinical study demonstrating that its topical [...]
Biosceptre appoints Sir Greg Winter as Chairman of the Board
Biosceptre is pleased to announce the appointment of Sir Greg [...]
Biosceptre Interviewed by Pharmaventures at Sachs Associates Conference, Basel
28th September, 2016 Daniel Barton spoke with Fintan Walton of [...]
Professor Francesco Di Virgilio joins Biosceptre Scientific Advisory Board
Press Release - Biosceptre announces today that Professor Francesco Di [...]
Biosceptre presents at leading Immuno-oncology Investment Conference in Chicago
Biosceptre represented at the 2nd Annual Immuno-Oncology: BD&L and Investment [...]